- Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer
- Eiger Updates on 2019 Progress and 2020 Milestones Expected
- Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies
- Eiger to Present at Jefferies 2019 London Healthcare Conference
- Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019
- Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update
As of last trade
Eiger BioPharmaceuticals Inc (72C1:STU) traded at 12.70, -9.29% below its 52-week high of 14.00, set on Dec 27, 2019.
8.33Jun 07 201914.00Dec 27 2019
Markit short selling activity
|Market cap||348.81m USD|
|EPS (TTM)||-3.33 |
Data delayed at least 15 minutes, as of Jan 22 2020.